Selected article for: "informed consent and right lung"
Author: Ridge, Carole A; Desai, Sujal R; Jeyin, Nidhish; Mahon, Ciara; Lother, Dione L; Mirsadraee, Saeed; Semple, Tom; Price, Susanna; Bleakley, Caroline; Arachchillage, Deepa J; Shaw, Elizabeth; Patel, Brijesh V; Padley, Simon PG; Devaraj, Anand
Title: Dual-Energy CT Pulmonary Angiography (DECTPA) Quantifies Vasculopathy in Severe COVID-19 Pneumonia
  • Cord-id: x8lkngra
  • Document date: 2020_10_29
    • ID: x8lkngra
    Snippet: BACKGROUND: The role of dual energy computed tomographic pulmonary angiography (DECTPA) in revealing vasculopathy in coronavirus disease 2019 (COVID-19) has not been fully explored. PURPOSE: To evaluate the relationship between DECTPA and disease duration, right ventricular dysfunction (RVD), lung compliance, D-dimer and obstruction index in COVID-19 pneumonia. MATERIALS AND METHODS: This institutional review board approved this retrospective study, and waived the informed consent requirement. B
    Document: BACKGROUND: The role of dual energy computed tomographic pulmonary angiography (DECTPA) in revealing vasculopathy in coronavirus disease 2019 (COVID-19) has not been fully explored. PURPOSE: To evaluate the relationship between DECTPA and disease duration, right ventricular dysfunction (RVD), lung compliance, D-dimer and obstruction index in COVID-19 pneumonia. MATERIALS AND METHODS: This institutional review board approved this retrospective study, and waived the informed consent requirement. Between March-May 2020, 27 consecutive ventilated patients with severe COVID-19 pneumonia underwent DECTPA to diagnose pulmonary thrombus (PT); 11 underwent surveillance DECTPA 14 ±11.6 days later. Qualitative and quantitative analysis of perfused blood volume (PBV) maps recorded: i) perfusion defect ‘pattern’ (wedge-shaped, mottled or amorphous), ii) presence of PT and CT obstruction index (CTOI) and iii) PBV relative to pulmonary artery enhancement (PBV/PAenh); PBV/PAenh was also compared with seven healthy volunteers and correlated with D-Dimer and CTOI. RESULTS: Amorphous (n=21), mottled (n=4), and wedge-shaped (n=2) perfusion defects were observed (M=20; mean age=56 ±8.7 years). Mean extent of perfusion defects=36.1%±17.2. Acute PT was present in 11/27(40.7%) patients. Only wedge-shaped defects corresponded with PT (2/27, 7.4%). Mean CTOI was 2.6±5.4 out of 40. PBV/PAenh (18.2 ±4.2%) was lower than in healthy volunteers (27 ±13.9%, p = 0.002). PBV/PAenh correlated with disease duration (β = 0.13, p = 0.04), and inversely correlated with RVD (β = -7.2, p = 0.001), persisting after controlling for confounders. There were no linkages between PBV/PAenh and D-dimer or CTOI. CONCLUSION: Perfusion defects and decreased PBV/PAenh are prevalent in severe COVID-19 pneumonia. PBV/PAenh correlates with disease duration and inversely correlates with RVD. PBV/PAenh may be an important marker of vasculopathy in severe COVID-19 pneumonia even in the absence of arterial thrombus.

    Search related documents:
    Co phrase search for related documents
    • acute pneumonia respiratory failure and admission prior: 1, 2
    • acute pneumonia respiratory failure and low molecular weight heparin: 1, 2, 3, 4, 5
    • acute pneumonia respiratory failure and lung compliance: 1
    • acute pneumonia respiratory failure and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute pulmonary embolism and admission prior: 1, 2, 3
    • acute pulmonary embolism and low molecular weight heparin: 1, 2, 3, 4, 5
    • acute pulmonary embolism and lung compliance: 1
    • acute pulmonary embolism and lung injury: 1, 2
    • acute respiratory failure and admission prior: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory failure and low compliance: 1, 2, 3, 4
    • acute respiratory failure and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory failure and lung compliance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • acute respiratory failure and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory failure and lung physiology: 1, 2, 3, 4, 5
    • acute respiratory sars syndrome and admission prior: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory sars syndrome and low compliance: 1, 2, 3, 4, 5, 6
    • acute respiratory sars syndrome and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory sars syndrome and lung compliance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory sars syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25